Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25683931 | 0.85 | PKM (0.32) | PKMSMN1; SMN2 | |
| SCHEMBL30393112 | 0.85 | PKM (0.32) | PKMSMN1; SMN2 | |
| SCHEMBL30392953 | 0.80 | CYP3A4 (0.38) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL25577923 | 0.80 | CYP3A4 (0.38) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23084799 | 0.73 | POLB (0.38) | KDM4EALDH1A1KCNA5 | |
| SCHEMBL29868237 | 0.73 | POLB (0.38) | KDM4EALDH1A1KCNA5 | |
| SCHEMBL29868093 | 0.73 | ALDH1A1 (0.36) | KDM4EALDH1A1SMN1; SMN2KCNA5 | |
| SCHEMBL23084690 | 0.73 | ALDH1A1 (0.36) | KDM4EALDH1A1SMN1; SMN2KCNA5 | |
| SCHEMBL30270924 | 0.71 | CHRM2 (0.32) | — | |
| SCHEMBL25943764 | 0.71 | CASP3 (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | KDM4E 2317/4885ALDH1A1 1718/4885PKM 2888/4885 |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | KDM4E 2317/4885ALDH1A1 1718/4885PKM 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.